welcome to cyprotexcloe® screencloe® selectcloe® predict

Investor News

January 5, 2009 - Directorate Changes

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, announces today that Nikolas Sofronis and Russell Barry Gibbs have resigned as directors of the Company with effect from 31 December 2008..

Commenting on the resignations, Steve Harris, Chairman of Cyprotex said:

"Both Nikolas and Russell have made significant contributions to the development of Cyprotex over the years for which we are extremely grateful. I thank them on behalf of the Company and wish them well in the future. Cyprotex is actively seeking candidates for the Board vacancies created by their resignations."

For further information:

Cyprotex PLC
Dr Anthony Baxter, CEO
Tel: +44 (0)1625 505 100
ir@cyprotex.com
www.cyprotex.com

Nomura Code Securities Limited:
Charles Walker, Corporate Finance
Tel: +44 (0)20 7776 1200
cew@nomuracode.com
www.nomuracode.com

Media Enquires:
Pelham PR

Simon Miller
Tel: +44 (0)20 743 6670
simon.miller@pelhampr.com

2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 3rd February 2012
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.